What is Denosumab and what are the notable side effects ?

-

Denosumab is a fully human monoclonal antibody that inhibits receptor activator of nuclear factor kappa-B (RANK) ligand, preventing activation of RANK, which disrupts osteoclast maturation and activation.

The most common adverse event overall was hypocalcemia, which occurred in 5% of patients despite supplementation with vitamin D and calcium. 

The most common severe adverse event was hypophosphatemia, which occurred in 3% of patients.

Osteonecrosis of the jaw is an infrequent but serious complication of treatment with denosumab. 

Comments

Post a Comment

Popular posts from this blog

Treatment of classical Hodgkin’s lymphoma Summary

-
Early stage favorable Hodgkin’s lymphoma ·          HD 10 trial: NEJM 2010: o    1370 pts, 4 arms: §   4 cycles of ABVD followed by 30 Gy §   4 cycles of ABVD followed by 20 Gy §   2 cycles of ABVD followed by 30 Gy §   2 cycles of ABVD followed by 20 Gy o    No difference in freedom from treatment failure, OS at 5 yrs o    2 cycles of ABVD followed by 20 Gy should be the new standard of care Unfavorable characteristics Bulky disease (>10 cm or 1/3 max. transverse thorax diameter Extranodal site involvement 3 or more lymph node areas involved ESR > 50 mm/h or > 30 mm/hr with B symptoms.                                       ...
Read more

Ovarian Cancer Summary

-
Epidemiology ·          5 th most common cancer among women. ·          Leading cause of gynecologic cancer death. ·          4% of cancers among women in the U.S. ·          Epithelial ovarian cancer accounts for 90% of all cases. ·          Fallopian tube cancer and primary peritoneal cancer are much rare, but share histologic, prognostic and treatment response features with epithelial ovarian cancer. ·          25% of women presents with stage I, 15% with stage II, 42% with stage III and 17% with stage IV. ·          10% of cancers of the ovary are non-epithelial. They are classified as either sex cord stromal cell tumors or germ cell tumors Risk factors and presentation ·   ...
Read more

CLL Summary

-
Epidemiology: CLL is the most prevalent adult leukemia in the western countries. It is more common in men than in women (ratio 1.7 to 1). There is no known risk factors for CLL. Median age at diagnosis between 67 and 72 years. Diagnosis: Sustained increase in mature appearing lymphocytes in the peripheral blood to more than 5,000/mm3. The majority of cases are B-CLL. IHC stains: CD5, low density expression of surface Ig, CD20 & CD22 unlike mantle cell lymphomas which has higher expression of CD20 and surface Ig. The bone marrow usually is infiltrated by at least 30% lymphocytes. Although a bone marrow biopsy is not needed to make the diagnosis, they are strongly recommended if cytopenias in other cell lines are present before starting therapy. Cytogenetic and molecular abnormalities Conventional techniques identify cytogenetic abnormalities in 50% of cases. FISH allows for identification of cytogenetic abnormalities in > 80% of cases...
Read more